ArticleJournal of molecular histology2026
Dendrobine promotes osteogenesis-angiogenesis in postmenopausal osteoporosis by inhibiting Hippo signaling pathway.
Article in Journal of molecular histology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Postmenopausal osteoporosis (PMOP) is a skeletal disorder marked by progressive bone mineral density decline and increased susceptibility to fractures. Accumulating evidence indicates that coupled osteogenesis and angiogenesis are indispensable for bone remodeling and repair. This study investigated the therapeutic potential of dendrobine in concurrently modulating osteogenic differentiation of bone marrow-derived mesenchymal stem cells (BMSCs) and angiogenic activity in the context of PMOP. BMSCs were isolated from Sprague-Dawley rats and rigorously characterized prior to experimentation. Cell viability was quantified using CCK-8 assays, and apoptosis was assessed via flow cytometry. To evaluate angiogenesis, tube formation capacity was measured following coculture of BMSCs and human umbilical vein endothelial cells (HUVECs), and protein levels of angiogenic factors (VEGF, MMP2, and MMP9) were quantified by western blotting. Osteogenic differentiation was assessed by Alizarin red staining for mineralized nodule formation, ALP staining, and western blotting of osteogenic markers (Runx2, OCN, and OPN). Following PMOP modeling via bilateral ovariectomy (OVX), H&E staining and micro-computed tomography were conducted. Western blotting was performed to measure protein levels of core Hippo pathway components (Mst1, Lats1, Yap1, and Taz) in femoral bone tissue. Results showed that dendrobine significantly promoted BMSC viability and suppressed apoptosis in a dose-dependent manner. In BMSC-HUVEC cocultures, dendrobine markedly augmented tube formation and upregulated VEGF, MMP2, and MMP9. Concurrently, dendrobine enhanced osteogenic differentiation, as evidenced by increased ALP activity, enhanced mineralization, and elevated protein levels of Runx2, OCN, and OPN. In OVX rats, dendrobine treatment ameliorated trabecular bone loss and restored bone parameters toward sham levels. Consistently, dendrobine elevated the expression of osteogenic and angiogenic proteins in vivo. Moreover, dendrobine suppressed Mst1 and Lats1 expression while promoting Yap1 and Taz expression in OVX rats. In conclusion, dendrobine alleviates PMOP by coordinately enhancing osteogenesis and angiogenesis through inhibition of the Hippo pathway and subsequent activation of the Yap1/Taz signaling.
Indexed as
Identifiers
42126726What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.